PA
TCRT icon

Parallel Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Parallel Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20
Closed -$5K – 3290
2021
Q3 		$5K Buy
+20
New +$6.12K ﹤0.01% 2391
2020
Q4 		– Sell
-67
Closed -$25K – 2715
2020
Q3 		$25K Hold
67
– – ﹤0.01% 1353
2020
Q2 		$32K Hold
67
– – ﹤0.01% 1222
2020
Q1 		$24K Buy
+67
New +$34.7K ﹤0.01% 1238

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parallel Advisors's TCRT Position: Q4 2021 in Review

Parallel Advisors sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 20 shares — an estimated $5K sold.

Parallel Advisors first reported a position in TCRT in Q1 2020 and held it in 4 quarters. The position peaked at $32K in Q2 2020. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

  • Parallel Advisors reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parallel Advisors sold 20 Alaunos Therapeutics shares in Q4 2021, an estimated $5K.
  • Parallel Advisors first reported a position in Alaunos Therapeutics in Q1 2020 and held it in 4 quarters.
  • Parallel Advisors's Alaunos Therapeutics position peaked at $32K in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.